Financial
Latest full-year results from official filings.
FY2025 revenue $2.23bn (-6.3%); operating margin 1.9%; net income $0.7m.
Cash $308.0m; debt $1.28bn.
- Official results release · ICU Medical · 31 Dec 2025
ICU Medical: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
May 2025: ICU Medical and Otsuka Pharmaceutical Factory completed formation of the Otsuka ICU Medical IV solutions joint venture for North America. Apr 2025: ICU Medical received an FDA warning letter (see regulatory).
- ICU Medical, Otsuka form joint IV supply venture · Pharmaceutical Processing World · 2 May 2025
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents, regulator action or published product security advisories involving ICU Medical found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Aug 2025: FDA classed a Plum Duo infusion pump software correction (pump may freeze, delaying therapy) as its most serious recall type; no injuries reported. Apr 2025: an FDA warning letter cited unapproved design changes to Medfusion 4000 and CADD Solis pumps.
- ICU Medical corrects Plum Duo infusion pump software · MassDevice · 28 Aug 2025
- FDA warning letter to ICU Medical over infusion pumps · Minnesota Star Tribune · 23 Apr 2025
Contract performance
Contract delivery, go-lives, terminations and disputes.
No notable troubled implementations, terminations, customer disputes or significant NHS contracts involving ICU Medical found in HSH's search of the last 24 months.